Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Research Letter

Puumala Virus Infection in Family, Switzerland

Figures
Article Metrics
1
citations of this article
EID Journal Metrics on Scopus
Pauline VetterComments to Author , Arnaud G. L’Huillier, Maria F. Montalbano, Fiona Pigny, Isabella Eckerle, Giulia Torriani, Sylvia Rothenberger, Florian Laubscher, Samuel Cordey, Laurent Kaiser, and Manuel SchiblerComments to Author 
Author affiliations: University of Geneva, Geneva, Switzerland (P. Vetter, A.G. L’Huillier, F. Pigny, G. Torriani, F. Laubscher, S. Cordey, L. Kaiser, M. Schibler); Geneva University Hospitals, Geneva (P. Vetter, M.F. Montalbano, F. Pigny, I. Eckerle, G. Torriani, F. Laubscher, S. Cordey, L. Kaiser, M. Schibler); Geneva Centre for Emerging Viral Diseases, Geneva (P. Vetter, I. Eckerle, G. Torriani, L. Kaiser); Spiez Laboratory, Spiez, Switzerland (S. Rothenberger); University of Lausanne, Lausanne, Switzerland (S. Rothenberger)

Cite This Article

Abstract

We report 3 cases of Puumala virus infection in a family in Switzerland in January 2019. Clinical manifestations of the infection ranged from mild influenza-like illness to fatal disease. This cluster illustrates the wide range of clinical manifestations of Old World hantavirus infections and the challenge of diagnosing travel-related hemorrhagic fevers.

Puumala orthohantavirus (PUUV), a species of the genus Orthohantavirus within the Hantaviridae family, is an enveloped single-strand negative-sense RNA virus (1). The case-fatality ratio of Old World hantaviruses ranges from 1%–10% for Dobrava-Belgrade and Hantaan orthohantaviruses to <1% for PUUV. Infection is transmitted by direct inhalation of virion-containing aerosols from rodent urine and feces. PUUV causes nephropathia epidemica, a limited form of hemorrhagic fever with renal syndrome (1). In Russia, 6,000–8,000 cases of hemorrhagic fever with renal syndrome are reported annually. Most cases occur in Western Russia and are caused by PUUV and Dobrava-Belgrade orthohantaviruses (2).

Asthenia, fever, chills, diffuse myalgia, and lumbar pain developed in a man 45 years of age 4 days after he returned to Switzerland from Samara, his hometown in central Russia (Appendix). Four days later, he sought treatment at the Geneva University Hospitals (Geneva, Switzerland) for septic shock with disseminated intravascular coagulation and kidney and liver failure. He had severe thrombocytopenia and elevated levels of C-reactive protein, procalcitonin, and leukocytes (Appendix Table 2). We transferred him to the intensive care unit for mechanical ventilation and hemodynamic support because of severe metabolic acidosis and confusion. We began treatment with broad-spectrum antimicrobial drugs, including doxycycline for possible leptospirosis. The day after admission, the patient tested positive for PUUV by real-time reverse transcription PCR (3) with a cycle threshold of 28. His serum sample tested positive for IgM and IgG against hantaviruses (Appendix Table 1). Shortly after his diagnosis, we administered 2 doses of 30 mg subcutaneous icatibant 6 hours apart. The patient died of multiple organ failure <60 hours after admission.

The next day, fever, lymphopenia, moderate thrombocytopenia, and hepatitis developed in the index patient’s daughter, who was 12 years of age (Appendix). She was hospitalized and tested positive for PUUV by PCR with a cycle threshold of 26. We prescribed a 5-day course of oral ribavirin starting with an initial dose of 30 mg/kg followed by 15 mg/kg every 6 hours (4). The viral load in plasma rapidly decreased. We did not detect viral RNA in urine (Appendix Table 3). Interstitial nephropathy briefly developed and subsided; she was discharged without sequelae after 7 days.

The wife of the index patient had had influenza-like symptoms in Russia during the week before her husband’s illness. Her serum sample tested positive for IgM and IgG against hantaviruses. We used a pseudovirus-based neutralization assay to confirm serologic results (Appendix Figure 1).

Figure

Phylogenetic tree of Puumala virus using S segment nucleotide sequences. Bold text indicates sequences isolated from family in Switzerland. GenBank accession numbers are provided in brackets. Lineages are indicated at right. Scale bar indicates number of substitutions per site.

Figure. Phylogenetic tree of Puumala virus using S segment nucleotide sequences. Bold text indicates sequences isolated from family in Switzerland. GenBank accession numbers are provided in brackets. Lineages are indicated at...

We sequenced the viral genome from blood samples taken from the father (GenBank accession no. MT822196) and the daughter (GenBank accession no. MT822195) using high-throughput sequencing (Appendix Figure 2). Both sequences showed a 100% segment match and were related to PUUV sequences in GenBank from Samara (Figure), confirming that the patients were exposed there. Regular outbreaks occur in Samara (5), where annual rodent control measures were delayed in 2019. In Switzerland, local acquisition of PUUV is rare (6).

This familial cluster highlights the wide spectrum of clinical manifestations of PUUV, which can range from an influenza-like illness (mother) to the classical nephropathy (daughter) to a rapidly fatal hemorrhagic fever with shock and multiple organ failure (father). Such a large spectrum of disease might be caused by the viral inoculum or host factors. Uncontrolled immune response and subsequent cytokine storm have been identified as key factors in the development of critical disease (7). Smoking, enzymatic polymorphisms, and gene variants such as HLA-B8 DRB1*03:02 (8) might be risk factors for severe disease, whereas HLA-B57 might have a protective effect (9). High procalcitonin levels, severe thrombocytopenia, increased interleukin 6 levels, and leukocytosis are known markers for severe disease.

Although specific antimicrobial drugs have been tested against PUUV infections, treatment is limited to supportive care. A small trial in Russia showed no effect of ribavirin on PUUV viral load or risk for death (10). We decided to treat the daughter with ribavirin because of her early diagnosis and treatment, the potential genetic factors that might predispose her to severe disease, and the emotional context of her father’s death. We treated the father with icatibant, a selective antagonist of the bradykinin type 2 receptor that reduces capillary leakage. This treatment has been used with apparent success in 2 patients with severe PUUV infection (Appendix).

PUUV usually causes limited renal disease but has a broad spectrum of clinical manifestations. Human hantavirus infections are rare in Switzerland and mostly acquired outside of the country. Physicians should consider viral hemorrhagic fevers when a patient has worsening influenza-like illness, thrombocytopenia, renal and hepatic impairment, and a plausible epidemiologic link to a region to which these viruses are endemic.

Dr. Vetter is an infectious diseases physician at Geneva University Hospitals and Geneva Centre for Emerging Viral Diseases, Geneva. Her research interests include emerging viral diseases.

Top

Acknowledgments

We thank Erik Boehm for editorial assistance. We thank Gert Zimmer for the donation of vesicular stomatitis virus recombinant, Jay W. Hooper from the United States Army Medical Research Institute of Infectious Diseases for the plasmid encoding Puumala glycoprotein, and Jennifer Mayor for the production of recombinant vesicular stomatitis virus with Puumala virus glycoprotein. We are deeply grateful to the family for their permission to publish this article.

This work was supported by the Geneva Center for Emerging Viral Diseases and Geneva University, Faculty of Medicine.

Top

References

  1. Manigold  T, Vial  P. Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology. Swiss Med Wkly. 2014;144:w13937. DOIPubMedGoogle Scholar
  2. Tkachenko  EA, Ishmukhametov  AA, Dzagurova  TK, Bernshtein  AD, Morozov  VG, Siniugina  AA, et al. Hemorrhagic fever with renal syndrome, Russia. Emerg Infect Dis. 2019;25:23258. DOIPubMedGoogle Scholar
  3. Kramski  M, Meisel  H, Klempa  B, Krüger  DH, Pauli  G, Nitsche  A. Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrosequencing. Clin Chem. 2007;53:1899905. DOIPubMedGoogle Scholar
  4. World Health Organization. Clinical management of patients with haemorragic fever. 2016 [cited 2020 Sep 30]. https://apps.who.int/iris/bitstream/handle/10665/205570/9789241549608_eng.pdf
  5. Alexeyev  OA, Suzdaltsev  AA, Verkhovtsev  VN, Efratova  ES, Roschupkin  VI. A major outbreak of hemorrhagic fever with renal syndrome in the Samara region, European Russia. Infection. 1998;26:322. DOIPubMedGoogle Scholar
  6. Fontana-Binard  L, Schultze  D, Rojanavisut  BS, Krüger  DH, Dollenmaier  G, Zanetti  G, et al. [First case of nephropathia epidemica acquired in Switzerland] [in French]. Rev Med Suisse. 2008;4:15725.PubMedGoogle Scholar
  7. Garanina  E, Martynova  E, Davidyuk  Y, Kabwe  E, Ivanov  K, Titova  A, et al. Cytokine storm combined with humoral immune response defect in fatal hemorrhagic fever with renal syndrome case, Tatarstan, Russia. Viruses. 2019;11:601. DOIPubMedGoogle Scholar
  8. Mäkelä  S, Mustonen  J, Ala-Houhala  I, Hurme  M, Partanen  J, Vapalahti  O, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J Infect Dis. 2002;186:8436. DOIPubMedGoogle Scholar
  9. Mustonen  J, Partanen  J, Kanerva  M, Pietilä  K, Vapalahti  O, Pasternack  A, et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol. 1998;47:2779. DOIPubMedGoogle Scholar
  10. Malinin  OV, Platonov  AE. Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by Puumala virus. Infect Dis (Lond). 2017;49:51420. DOIPubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2702.203770

Original Publication Date: January 19, 2021

Table of Contents – Volume 27, Number 2—February 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Pauline Vetter, Geneva Center for Emerging Viral Diseases, Geneva University Hospitals, 4, rue Gabrielle-Perret Gentil, 1205 Geneva, Switzerland

Send To

10000 character(s) remaining.

Top

Page created: November 13, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external